356 related articles for article (PubMed ID: 17532030)
1. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
2. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
3. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
4. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
5. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer.
Yoshimura M; Nishimura R; Murotani A; Miyamoto Y; Nakagawa T; Hasegawa K; Koizumi T; Shii K; Baba S; Tsubota N
Cancer; 1994 Jun; 73(11):2745-52. PubMed ID: 7514953
[TBL] [Abstract][Full Text] [Related]
6. Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders.
Neven P; Iles RK; Lee CL; Hudson CN; Shepherd JH; Chard T
Cancer; 1993 Jun; 71(12):4124-30. PubMed ID: 7685240
[TBL] [Abstract][Full Text] [Related]
7. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor.
Huang CY; Cheng WF; Lee CN; Su YN; Chien SC; Tzeng YL; Hsieh CY; Chen CA
Anticancer Res; 2006; 26(6C):4721-8. PubMed ID: 17214332
[TBL] [Abstract][Full Text] [Related]
8. Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers.
Kinugasa M; Nishimura R; Koizumi T; Morisue K; Higashida T; Natazuka T; Nakagawa T; Isobe T; Baba S; Hasegawa K
Jpn J Cancer Res; 1995 Aug; 86(8):783-9. PubMed ID: 7559103
[TBL] [Abstract][Full Text] [Related]
9. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
11. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
Creaney J; Musk AW; Robinson BW
J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
[TBL] [Abstract][Full Text] [Related]
13. Increases urinary HMGA1 in serous epithelial ovarian cancer patients.
Zhou J; Xie M; He H; Shi Y; Luo B; Gong G; Li J; Wang J; Wu X; Wen J
Cancer Biomark; 2015; 15(3):325-31. PubMed ID: 25586095
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity of hCGbeta--related glycoproteins and the clinical relevance in trophoblastic and non-trophoblastic tumors.
Nishimura R; Koizumi T; Yokotani T; Taniguchi R; Morisue K; Yoshimura M; Hiranmoy D; Yamaguchi S; Nakagawa T; Hasegawa K; Yasui H
Int J Gynaecol Obstet; 1998 Apr; 60 Suppl 1():S29-32. PubMed ID: 9833612
[TBL] [Abstract][Full Text] [Related]
15. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study.
Macuks R; Baidekalna I; Donina S
Asian Pac J Cancer Prev; 2012; 13(9):4695-8. PubMed ID: 23167404
[TBL] [Abstract][Full Text] [Related]
16. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
17. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
18. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
Cole LA; Nam JH
Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
[TBL] [Abstract][Full Text] [Related]
19. The origin of a human chorionic gonadotropin beta-subunit-core fragment excreted in the urine of patients with cancer.
Papapetrou PD; Nicopoulou SC
Acta Endocrinol (Copenh); 1986 Jul; 112(3):415-22. PubMed ID: 2428192
[TBL] [Abstract][Full Text] [Related]
20. Following metastatic placental site trophoblastic tumor with urine beta-core fragment.
Rinne K; Shahabi S; Cole L
Gynecol Oncol; 1999 Aug; 74(2):302-3. PubMed ID: 10419751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
